Global Antacids Market – Industry Trends and Forecast to 2030

Antacids Market Analysis and Size

The global antacids market is expected to witness significant growth during the forecast period. Growing cases of gastric ulcers, heartburn and ingestion drive the antacids market. However, easily availability of antacids OTC drugs and the rising prevalence of gastric diseases will also enhance the antacids market. Researchers are developing new drugs that help boost the market growth. Many major market players are contributing a lot to drug discovery and development. COVID-19 also had a major impact on the market growth.

Data Bridge Market Research analyses that the global antacids market which was USD 6,958.64 million in 2022, would rocket up to USD 9,756.34 million by 2030, and is expected to undergo a CAGR of 5.2% during the forecast period. This indicates that the market value. “Sodium Antacids” dominates the type segment of the antacids market owing to the high demand for this type of product. In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.

Antacids Market Scope and Segmentation

Market Definition

Antacids are the medical agents that help neutralize acid present in the stomach. The normal pH of gastric acid is in the range of 1.5-3.5. Antacids are alkaline and contain sodium, aluminum, magnesium and calcium. The alkaline nature of antacids assists in neutralizing gastric acid. In contrast to this, antacids relieve pain, inflammation and gastric acidity. It is of great importance to the healthcare sector and thus is expected to rise high in the forecast period.

Global Antacids Market Dynamics

Drivers

• Rising Awareness For GERD

The rising awareness about GERD is expected to boost market growth. As per the reports of the International Foundation for Gastrointestinal Disorders, the 19th Annual GERD Awareness Week provided information and support associated with this condition in November 2018. In addition, the International Foundation for Functional Gastrointestinal Disorders (IFFGD) boosts patients suffering from GERD-related symptoms to visit physicians.

• Increase in Geriatric Population

As per the reports of the United Nations World Ageing 2019, in 2019, there were approximately 703 million people who were aged 65 years or over globally. It is expected to increase to 1.5 billion in 2050. Globally, the share of the population aged 65 years or over increased from 6% in 1990 to 9% in 2019, and almost 65% of the elderly population has to deal with acid reflux. This creates an opportunity for the market.

• Growing investment for healthcare facilities

Surging focus on improving the condition of healthcare facilities and improving the overall healthcare infrastructure is another important factor fostering the growth of the market. The rising number of partnerships and strategic collaborations between the public and private players pertaining to funding and application of new and improved technology is further creating lucrative market opportunities.  

Opportunities

• Increasing Demand for Retail Pharmacies

The rise in the number of antacids being delivered through retail pharmacies and the surge in the number of retail pharmacies in developed countries create opportunities for market growth. In addition to this, patients prefer retail pharmacies for purchasing drugs, as these are easily accessible.

• Rising Cases of Heartburn

The growing prevalence of heartburn is expected to boost the market over the forecast period. As per the reports of Medical Xpress, a web-based medical and health news service, researchers from the University of Michigan recognized that acid reflux and heartburn affected more than 20% of the U.S. population in 2017.

Restraints/Challenges

• Rising competition

The antacids market is highly competitive, with numerous companies offering a wide range of products. This can make it challenging for new entrants or smaller companies to gain market share and establish a strong presence.

• Side effects and safety concerns

Antacids, especially those containing aluminum or magnesium, can have side effects such as constipation or diarrhea. Additionally, long-term use of certain antacids has been associated with potential health risks, such as kidney problems. These safety concerns can affect consumer confidence and lead to a decline in sales.

This antacids market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, the impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the global antacids market, contact Data Bridge Market Research for an Analyst Brief. Our team will help you make an informed market decision to achieve market growth.

Recent Developments

• In 2021, Sanofi announced a partnership with Roche to develop and commercialize a novel antacid product for the treatment of gastroesophageal reflux disease (GERD). This collaboration aims to bring a new treatment option to patients suffering from GERD
• In 2021, Johnson & Johnson announced the launch of their antacid product, Pepcid Complete, which combines an acid reducer (famotidine) with an antacid (calcium carbonate). This combination is aimed at providing dual-action relief for heartburn symptoms.

Global Antacids Market Scope

The antacids market is segmented on the basis of type, indication, dosage form, route of administration, distribution channel and end-user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Type

• Sodium Antacids
• Calcium Antacids
• Magnesium Antacids
• Aluminium Antacids
• Others

Indication

• Gastroesophageal Reflux Disease
• Heartburn
• indigestion
• Others

Dosage Form

• Tablets
• Liquid
• Others

Route of Administration

• Oral
• Others

End-Users

• Hospitals
• Homecare
• Speciality Centres
• Others

Distribution Channel

• Hospital Pharmacy
• Online Pharmacy
• Retail Pharmacy

Global Antacids Market Regional Analysis/Insights

The antacids market is analysed and market size insights and trends are provided by country, type, indication, dosage form, route of administration, distribution channel and end-user, as referenced above.

The countries covered in the antacids market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

North America is expected to dominate the antacids Market because of the strong base of healthcare facilities, strong presence of major players in the market, and rising number of research activities in this region.   

Asia-Pacific is expected to witness significant growth during the forecast period of 2023 to 2030 due to the increase in government initiatives to promote awareness, rise in healthcare facilities, growing research activities in the region, availability of massive untapped markets, large population pool, and the growing demand for quality healthcare in the region.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, and case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, the impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.   

Healthcare Infrastructure Growth Installed Base and New Technology Penetration

The antacids market also provides you with detailed market analysis for every country's growth in healthcare expenditure for capital equipment, installed base of different kind of products for the antacids market, the impact of technology using lifeline curves and changes in healthcare regulatory scenarios and their impact on the antacids market. The data is available for the historic period 2015-2020.

Competitive Landscape and Global Antacids Market Share Analysis

The global antacids market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to global antacids market.

Some of the major players operating in the global antacids market are:

• Pfizer Inc (U.S.)
• F. Hoffmann-La Roche Ltd (Switzerland)
• Mylan N.V. (U.S.)
• Fresenius Kabi AG (Germany)
• Hikma Pharmaceuticals PLC (Japan)
• Novartis AG (Switzerland)
• Teva Pharmaceutical Industries Ltd. (Israel)
• Bristol Myers Squibb Company (U.S.
• GSK Plc. (U.K.)
• Bayer AG (Germany)
• Sun Pharmaceutical Industries Ltd (India)
• Lupin (India)
• Cipla Inc (India)
• Aurobindo Pharma (India)
• Procter & Gamble (U.S.)
• Reckitt Benckiser Group PLC (U.K.)

SKU-53884